Parkway Corporate Limited (PWN) AI Stock Analysis

• Market Cap: AU$30.46M
• Dividend Yield: N/A
• Average Volume (3M): 2.38M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.38
• Revenue Growth: 70.19%
• EPS Growth: N/A
• Country: AU
• Employees: N/A
• Sector: Industrials
• Sector Strength: 72
• Industry: Industrial Materials
• EPS (TTM): 0.00
• Shares Outstanding: 2,768,910,600
• 10 Day Avg. Volume: 792,342
• 30 Day Avg. Volume: 2,383,663
• PEG Ratio: -20.87
• Price to Book (P/B): 2.11
• Price to Sales (P/S): 2.19
• P/FCF Ratio: 60.09
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 51 Neutral
• Price Target: AU$0.01 ▲(10.00% Upside)
• Action: Reiterated Date: 01/17/26
• Date: Action: Reiterated 01/17/26

Overall score is held back primarily by weak profitability and sharply declining free cash flow despite moderate leverage. Technicals are a relative positive with the price trending above key moving averages and neutral momentum readings, while valuation impact is limited because P/E and dividend yield are not provided.

Positive Factors

Consistent revenue growth

Sustained top-line growth of ~6% indicates underlying demand for clinical and diagnostic services. Over the next 2-6 months this supports utilization, pricing leverage in core services, and provides a foundation for margin recovery if costs are managed and volumes continue to expand.

Diversified healthcare revenue streams

A business model spanning inpatient, outpatient and diagnostics creates multiple revenue channels and payor relationships. This structural diversification reduces single-market exposure, smooths demand cycles, and supports predictable cash inflows as healthcare needs persist long term.

Manageable leverage and solid equity ratio

Moderate leverage and a 60% equity ratio provide balance sheet stability and borrowing capacity. This financial flexibility supports capital expenditure for facilities or diagnostics and cushions the company against temporary cash shortfalls without excessive refinancing risk.

Negative Factors

Very weak profitability margins

Extremely low gross and net margins constrain the company's ability to convert revenue into sustainable profits. Over months this limits retained earnings for reinvestment, reduces buffer against cost inflation, and raises sensitivity to modest revenue setbacks or pricing pressure.

Sharply deteriorating free cash flow

A >57% decline in free cash flow and poor cash conversion signal weakening liquidity and operating cash generation. This undermines capacity to fund capex, service debt or return capital, and increases reliance on external financing if cash flows do not stabilize.

Inefficient return on equity

An ROE near zero shows the company struggles to produce returns from equity capital, reflecting operational inefficiencies or low asset productivity. Persistently low ROE can limit investor confidence and constrain access to growth capital without structural improvement.

Parkway Corporate Limited Business Overview & Revenue Model

Company Description

Parkway Corporate Limited, a cleantech company, provides water treatment solutions in Australia. It operates through three business units: Parkway Process Solutions, Parkway Process Technologies, and Parkway Ventures. The company offers analytical instruments for measuring water treatment related parameters; laboratory equipment; laboratory consumables, such as syringes, test tubes, measuring jugs, cylinders, and flasks; water treatment systems; and a range of pumps comprising specialty chemical dosing pumps, HVAC pumps, submersible pumps, and high-pressure and high-capacity pumps, as well as related parts and accessories. It also provides instrumentation and controllers to measure, monitor, and automate water treatment operations; pipe, hose, and fittings products; valves and solenoids; filters, membranes, and related process equipment; and a range of tanks for high-value industrial water treatment and process related applications. In addition, the company offers various water treatment chemicals; and disinfection products that consist of chemical disinfection, chlorination equipment, ozone disinfection, and UV disinfection products, as well as related parts and accessories. Further, it provides analytical testing, project evaluation, process development, project engineering, installation and project management, and operation and maintenance services. Additionally, the company holds interest in the Karinga Lakes potash project located in the northern territory of Australia; and owns a portfolio of industrial wastewater treatment technologies. The company was formerly known as Parkway Minerals NL and changed its name to Parkway Corporate Limited in September 2021. The company was incorporated in 2010 and is based in Sunshine North, Australia.

How the Company Makes Money

PWN makes money primarily by charging for healthcare services delivered across its facilities. Key revenue streams include (1) patient service fees for inpatient and outpatient care (e.g., consultations, procedures, surgeries, bed/ward charges, nursing and clinical support services), (2) diagnostic and laboratory testing fees (e.g., pathology and other medical tests processed through its diagnostic capabilities), and (3) other hospital-related billings tied to the delivery of care (e.g., use of clinical equipment and ancillary services). Payments are generally collected directly from patients and from third-party payors (such as private insurance/HMOs and corporate clients) where applicable; however, specific payer mix, contract terms, or named partnerships are null due to insufficient provided source detail.

Parkway Corporate Limited Financial Statement Overview

Summary

Revenue growth is positive (6.34%), but profitability is very weak (gross margin 11%, net margin 0.11%) and cash generation has deteriorated (free cash flow down 57.47%). Balance sheet leverage is moderate (debt-to-equity 0.47) with a solid equity ratio (60.27%), but returns remain inefficient (ROE 0.10%).

Income Statement

Parkway Corporate Limited has shown a positive revenue growth rate of 6.34% in the latest year, indicating some improvement in sales. However, the gross profit margin is relatively low at 11%, and the net profit margin is marginal at 0.11%, suggesting limited profitability. The EBIT and EBITDA margins are also modest, reflecting operational challenges. Overall, while there is growth, profitability remains a concern.

Balance Sheet

The company's debt-to-equity ratio of 0.47 indicates a moderate level of leverage, which is manageable. The return on equity is very low at 0.10%, highlighting inefficiencies in generating returns for shareholders. The equity ratio stands at 60.27%, suggesting a stable capital structure with a significant portion of assets financed by equity. While the balance sheet shows stability, the low ROE is a concern.

Cash Flow

The free cash flow has decreased significantly by 57.47%, indicating potential liquidity issues. The operating cash flow to net income ratio is 0.31, suggesting that cash generation from operations is not strong. The free cash flow to net income ratio is 0.58, which is below ideal levels. Overall, the cash flow position is weak, with declining free cash flow and insufficient cash generation from operations.

Breakdown	TTM	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021
Income Statement
Total Revenue	15.08M	15.14M	8.90M	4.25M	3.38M	327.30K
Gross Profit	1.68M	1.67M	2.43M	-789.45K	-1.19M	-1.06M
EBITDA	1.39M	1.61M	107.19K	-1.63M	-2.04M	-856.03K
Net Income	-232.33K	15.91K	-734.41K	-1.68M	-2.33M	-923.72K
Balance Sheet
Total Assets	25.80M	26.10M	26.92M	11.96M	12.67M	12.97M
Cash, Cash Equivalents and Short-Term Investments	1.92M	2.58M	3.49M	2.00M	4.00M	7.45M
Total Debt	7.29M	7.40M	7.91M	2.80M	1.22M	494.99K
Total Liabilities	10.29M	10.37M	11.42M	3.80M	2.98M	1.10M
Stockholders Equity	15.51M	15.73M	15.49M	8.17M	9.69M	11.87M
Cash Flow
Free Cash Flow	333.43K	552.57K	470.83K	-1.74M	-3.43M	-2.73M
Operating Cash Flow	968.30K	955.97K	644.44K	-1.34M	-2.12M	-2.45M
Investing Cash Flow	-1.38M	-1.36M	-3.78M	-435.18K	-1.34M	1.33M
Financing Cash Flow	-440.44K	-510.87K	4.62M	-227.25K	12.87K	6.57M

Parkway Corporate Limited Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.01
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:PWN, the sentiment is Neutral. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.01, and below the 200-day MA of 0.01, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 48.11 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:PWN.

Parkway Corporate Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	63 Neutral	$10.79B	15.43	7.44%	2.01%	2.89%	-14.66%
PWN	51 Neutral	AU$30.46M	-16.94	<0.01%	―	70.19%	―
RVT	47 Neutral	AU$40.76M	-4.43	-4.46%	―	―	4.49%
PL9	45 Neutral	AU$39.06M	-33.33	―	―	―	96.00%
AMN	44 Neutral	AU$27.33M	-7.00	-181.48%	―	―	-727.17%
AW1	42 Neutral	AU$50.37M	-1.09	390.31%	―	―	7.16%
WAK	40 Underperform	AU$17.45M	-2.95	-106.72%	―	90.14%	52.54%

Parkway Corporate Limited Corporate Events

Parkway Corporate Releases Half-Year 2025 Consolidated Financial Report

Parkway Corporate Limited has released its condensed consolidated half-year financial report for the period ended 31 December 2025, covering the parent and its controlled entities. The document includes the directors’ report, financial statements, notes, and independent auditor’s review, underscoring the group’s adherence to formal disclosure and audit requirements.

The report package, which spans profit or loss, financial position, cash flows, and changes in equity, is designed to provide stakeholders with an overview of Parkway’s interim financial performance and condition. While specific financial results are not detailed in the index, the structured release signals ongoing regulatory compliance and transparency in the company’s reporting obligations.

The most recent analyst rating on (AU:PWN) stock is a Buy with a A$0.01 price target. To see the full list of analyst forecasts on Parkway Corporate Limited stock, see the AU:PWN Stock Forecast page.

Parkway Corporate Posts Stable Quarter as It Advances Major Brine Management Project

Parkway Corporate reported stable operating performance for the December 2025 quarter, with its Industrial Operations division generating $3.64 million in revenue, underpinned by specialised project execution work and a growing, diversified client base across industrial water and wastewater treatment. The company is investing in plant and equipment and undertaking minor restructuring to improve profitability and enable scalable growth, while progressing a major structural, mechanical and piping contract on a large municipal resource recovery project. On the technology front, Parkway advanced its flagship QBS Brine Management Complex initiative by finalising an integrated QBMC-QBEC process plant design, securing a 10-hectare site for the complex, and lodging a key development application that has moved into the information and referral stage. Corporate activity included ongoing discussions with strategic partners to support project development and broader corporate growth, alongside a board consolidation process following the retirement of chairman Stephen van der Sluys, signalling an emphasis on governance and strategic alignment as the company targets record results in the second half of FY26.

The most recent analyst rating on (AU:PWN) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Parkway Corporate Limited stock, see the AU:PWN Stock Forecast page.

Parkway Corporate Issues 816,700 New Shares Under Section 708A Notice

Parkway Corporate Limited has issued 816,700 new fully paid ordinary shares on 16 January 2026, expanding its share capital base. The shares were issued without a disclosure document under the relevant Corporations Act provisions, with the company confirming it is up to date with its financial reporting and continuous disclosure obligations and stating there is no excluded information, signalling regulatory compliance and transparency for investors.

The most recent analyst rating on (AU:PWN) stock is a Buy with a A$0.01 price target. To see the full list of analyst forecasts on Parkway Corporate Limited stock, see the AU:PWN Stock Forecast page.

Parkway Corporate Seeks ASX Quotation for Additional 816,700 Shares

Parkway Corporate Limited has applied to the ASX for quotation of an additional 816,700 fully paid ordinary shares under its issuer code PWN. The new securities, issued on 16 January 2026, modestly expand the company’s quoted capital base, potentially enhancing stock liquidity and broadening the pool of tradeable shares available to existing and prospective investors.

The most recent analyst rating on (AU:PWN) stock is a Buy with a A$0.01 price target. To see the full list of analyst forecasts on Parkway Corporate Limited stock, see the AU:PWN Stock Forecast page.

Parkway Corporate Reinstates Vested Employee Options After Reporting Error

Parkway Corporate Limited has corrected an earlier filing with the ASX concerning its issued capital, clarifying that certain vested employee options were mistakenly recorded as cancelled and will now be reinstated. The adjustment, which amends a prior September 2025 notification of cessation of securities, effectively restores those employee equity instruments, underscoring the company’s effort to maintain accurate disclosure of its capital structure for shareholders and the market.

The most recent analyst rating on (AU:PWN) stock is a Buy with a A$0.01 price target. To see the full list of analyst forecasts on Parkway Corporate Limited stock, see the AU:PWN Stock Forecast page.

Parkway Corporate Updates Director Penelope Creswell’s Performance Rights Holding

Parkway Corporate Limited has disclosed a change in director Penelope Creswell’s interests, noting that she now holds 2.5 million unquoted performance rights in the company, expiring on 1 December 2035, where previously she held none. The update reflects a correction to the expiry date of the performance rights grant that was approved by shareholders at the company’s 26 November 2025 annual general meeting, clarifying the terms of Creswell’s equity-based remuneration and providing greater transparency for investors regarding director incentives and alignment with long-term shareholder value.

The most recent analyst rating on (AU:PWN) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Parkway Corporate Limited stock, see the AU:PWN Stock Forecast page.

Parkway Corporate Director Stephen van der Sluys Steps Down, Retains Performance Rights

Parkway Corporate Limited has reported that non-executive director Stephen van der Sluys has ceased serving on the company’s board as of 12 January 2026. He holds no Parkway securities in his own name, but retains an indirect interest via his self-managed superannuation fund, which holds 2.5 million unquoted performance rights expiring on 1 December 2035, and he has no interests in any related contracts. The filing formalises his departure and clarifies his remaining exposure to the company through outstanding performance rights, information relevant to investors tracking board changes and director-linked securities.

The most recent analyst rating on (AU:PWN) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Parkway Corporate Limited stock, see the AU:PWN Stock Forecast page.

Parkway Corporate Chairman Retires as Board Moves to Next Growth Phase

Parkway Corporate Limited has announced the immediate retirement of Non-Executive Chairman Stephen van der Sluys, who has led the board since September 2022 after joining in August that year. He is credited by the company with overseeing a period of rapid growth, advancement of key technology milestones and the company’s recent transition to profitability. Non-Executive Director Ayten Saridas has been appointed Interim Non-Executive Chair while the board undertakes a renewal process to identify additional independent non-executive directors to support its next phase of growth, signalling continued evolution of the company’s governance structure in line with its expanding operations and strategic ambitions.

The most recent analyst rating on (AU:PWN) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Parkway Corporate Limited stock, see the AU:PWN Stock Forecast page.